Skip to content
OpenCapital
Get started

Savara SVRA Enterprise value

Enterprise value at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$1.15B+8.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$452.74M+5.3%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$1.39B+9.7%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$588.13M+55.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.72B+5.8%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$684.98M+89.8%

Other financials

Income statement

See full
Revenue-—
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
P/S4,648.7×—

Profitability

See full
Operating margin-19,183.3%—
Net margin-19,305.1%—
FCF margin-15,518.7%—

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

$1.1Bmarket cap+$30.1Mtotal debt−$38.8Mcash and equivalents=$1.11B

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's enterprise value?
Savara (SVRA) reported enterprise value of $1.11B in Q1 2026.
How has Savara's enterprise value changed year-over-year?
Savara's enterprise value increased by 127.1% year-over-year, from $488.16M to $1.11B.
What is the long-term trend for Savara's enterprise value?
Over 5 years (2020 to 2025), Savara's enterprise value has grown at a 68.2% compound annual growth rate (CAGR), from $91.02M to $1.22B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.